Profile data is unavailable for this security.
About the company
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
- Revenue in USD (TTM)2.80bn
- Net income in USD657.01m
- Incorporated1998
- Employees2.64k
- LocationGenmab A/SCarl Jacobsens Vej 30VALBY 2500DenmarkDNK
- Phone+45 70202728
- Fax+45 70202729
- Websitehttps://www.genmab.com/
More ▼
Mergers & acquisitions
| Acquired company | GMAB:CPH since announced | Transaction value |
|---|---|---|
| ProfoundBio US Co | -27.23% | 1.80bn |
Data delayed at least 15 minutes, as of Nov 14 2024 16:10 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revolution Medicines Inc | 742.00k | -567.06m | 9.78bn | 490.00 | -- | 6.23 | -- | 13,178.70 | -3.59 | -3.59 | 0.0047 | 9.34 | 0.0005 | -- | 4.80 | 1,962.96 | -41.28 | -29.76 | -44.46 | -32.59 | -- | -- | -76,423.31 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Exelixis Inc | 2.08bn | 466.92m | 10.05bn | 1.31k | 22.42 | 4.42 | 20.32 | 4.83 | 1.57 | 1.57 | 6.92 | 7.96 | 0.7012 | 3.39 | 8.04 | 1,589,006.00 | 15.73 | 8.86 | 18.08 | 9.91 | 96.25 | 96.30 | 22.43 | 15.43 | 3.88 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.06bn | 413.08m | 10.56bn | 20.00k | 25.78 | 2.79 | 13.75 | 2.60 | 8.01 | 8.01 | 78.63 | 73.97 | 0.5203 | 8.27 | 5.23 | 203,045.80 | 5.48 | 6.46 | 6.33 | 7.62 | 35.93 | 36.99 | 10.54 | 11.58 | 1.14 | 4.96 | 0.3784 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Tempus AI Inc | 640.44m | -800.71m | 10.72bn | 2.30k | -- | 196.81 | -- | 16.74 | -8.29 | -8.29 | 4.44 | 0.3459 | -- | -- | -- | -- | -- | -- | -- | -- | 53.18 | -- | -116.06 | -- | 2.55 | -14.95 | 0.891 | -- | 65.85 | -- | 20.35 | -- | -- | -- |
| Sarepta Therapeutics Inc | 1.64bn | 121.85m | 10.74bn | 1.31k | 92.50 | 8.80 | 66.95 | 6.55 | 1.22 | 1.22 | 16.30 | 12.79 | 0.489 | 0.5703 | 4.35 | 1,248,362.00 | 3.63 | -21.63 | 4.38 | -25.75 | 85.92 | 86.65 | 7.43 | -77.05 | 3.03 | -- | 0.5013 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
| Medpace Holdings Inc | 2.07bn | 365.57m | 11.25bn | 5.90k | 31.69 | 12.73 | 28.52 | 5.43 | 11.42 | 11.42 | 64.70 | 28.42 | 1.16 | -- | 6.85 | 350,994.30 | 20.48 | 13.94 | 43.51 | 23.18 | 29.69 | 28.84 | 17.66 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Vaxcyte Inc | 0.00 | -507.65m | 12.04bn | 254.00 | -- | 3.52 | -- | -- | -4.55 | -4.55 | 0.00 | 27.47 | 0.00 | -- | -- | 0.00 | -20.08 | -34.22 | -20.95 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| BIO-TECHNE Corp | 1.17bn | 150.68m | 12.06bn | 3.10k | 80.76 | 5.64 | 46.04 | 10.30 | 0.9402 | 0.9402 | 7.29 | 13.46 | 0.4267 | 2.15 | 5.47 | 377,930.00 | 5.49 | 9.42 | 5.77 | 10.04 | 65.93 | 67.29 | 12.86 | 21.41 | 3.26 | 18.07 | 0.123 | 22.79 | 1.97 | 10.17 | -41.07 | 11.86 | 19.87 | 0.00 |
| Insmed Inc | 342.96m | -864.29m | 12.63bn | 912.00 | -- | 26.12 | -- | 36.83 | -5.56 | -5.56 | 2.21 | 2.70 | 0.2031 | 0.8848 | 8.81 | 376,050.40 | -51.17 | -40.96 | -59.16 | -46.88 | 77.25 | 77.99 | -252.01 | -212.92 | 5.99 | -18.41 | 0.6702 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
| Neurocrine Biosciences, Inc. | 2.24bn | 385.90m | 12.71bn | 1.70k | 33.61 | 4.67 | 30.87 | 5.67 | 3.73 | 3.73 | 21.67 | 26.87 | 0.7027 | 0.8901 | 4.99 | 1,602,000.00 | 12.09 | 9.77 | 14.67 | 12.19 | 98.52 | 98.51 | 17.21 | 14.79 | 4.26 | 10.28 | 0.00 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| Summit Therapeutics Inc | 0.00 | -196.68m | 14.36bn | 105.00 | -- | 32.77 | -- | -- | -0.2768 | -0.2768 | 0.00 | 0.5941 | 0.00 | -- | -- | 0.00 | -54.53 | -77.32 | -71.71 | -86.35 | -- | -- | -- | -20,989.46 | -- | -- | 0.053 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Genmab A/S - ADR | 2.80bn | 657.01m | 14.62bn | 2.64k | 21.43 | 3.04 | 34.74 | 5.22 | 1.01 | 1.01 | 4.30 | 7.12 | 0.5277 | 10.98 | 3.37 | 1,269,952.00 | 12.39 | 17.43 | 13.76 | 18.59 | 96.08 | -- | 23.47 | 35.87 | 5.15 | -- | 0.03 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
| Moderna Inc | 5.08bn | -2.22bn | 16.20bn | 5.60k | -- | 1.36 | -- | 3.19 | -5.81 | -5.81 | 13.14 | 30.98 | 0.2883 | 2.44 | 2.96 | 907,321.40 | -12.62 | 20.95 | -15.52 | 29.51 | 78.43 | -- | -43.77 | 32.10 | 4.20 | -- | 0.0521 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
| ICON PLC | 8.31bn | 747.89m | 16.83bn | 42.25k | 22.67 | 1.72 | 13.05 | 2.03 | 8.99 | 8.99 | 99.87 | 118.39 | 0.4852 | -- | 2.99 | 202,112.50 | 4.37 | 3.93 | 5.24 | 4.80 | 29.65 | 28.91 | 9.00 | 7.37 | -- | 4.41 | 0.2599 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
| United Therapeutics Corporation | 2.76bn | 1.11bn | 17.88bn | 1.17k | 17.60 | 2.93 | 15.18 | 6.49 | 22.75 | 22.75 | 56.36 | 136.74 | 0.3897 | 2.43 | 9.18 | 2,359,760.00 | 15.71 | 10.38 | 17.73 | 11.27 | 88.94 | 91.47 | 40.31 | 29.25 | 4.41 | -- | 0.0615 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
Data as of Nov 14 2024. Currency figures normalised to Genmab A/S's reporting currency: US Dollar USD
5.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AllianceBernstein LPas of 30 Jun 2024 | 15.24m | 2.30% |
| Capital Research & Management Co. (International Investors)as of 30 Jun 2024 | 4.23m | 0.64% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 4.20m | 0.64% |
| Harding Loevner LPas of 30 Jun 2024 | 2.77m | 0.42% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 2.29m | 0.35% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 1.46m | 0.22% |
| First Trust Advisors LPas of 30 Jun 2024 | 1.21m | 0.18% |
| Envestnet Asset Management, Inc.as of 30 Sep 2024 | 1.04m | 0.16% |
| Managed Account Advisors LLCas of 30 Jun 2024 | 716.40k | 0.11% |
| Two Sigma Investments LPas of 30 Jun 2024 | 709.58k | 0.11% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
